Alzheimer’s disease (AD) involves early molecular changes beyond amyloid-β (Aβ) and tau, that create heterogeneous disease biology, giving rise to variable disease initiation and highly variable longitudinal trajectories. The gene discussed is MAPT; the disease is Alzheimer disease.